| 摘要: |
| 神经营养性受体酪氨酸激酶（NTRK）基因融合是多种实体肿瘤的致癌驱动因素，是重要的临床生物标志物。在甲状腺癌中，NTRK基因融合阳性的患者表现出独特的临床病理特征，因此晚期、转移性或碘难治性甲状腺癌患者应该接受NTRK基因融合状态的评估。然而，关于甲状腺癌中NTRK基因融合的诊断和治疗目前还没有权威的建议或标准化的程序。本文综述了NTRK基因融合阳性甲状腺癌的研究进展，重点阐述了该疾病的临床病理特征，以及NTRK基因融合检测和靶向治疗药物的研究现状。 |
| 关键词: 甲状腺肿瘤 神经营养性受体酪氨酸激酶 基因融合 靶向治疗 |
| DOI：10.16781/j.CN31-2187/R.20240256 |
| 投稿时间：2024-02-19修订日期：2024-09-25 |
| 基金项目:海军军医大学（第二军医大学）第一附属医院青年培育项目（2021JCQN01）. |
|
| NTRK gene fusion in thyroid cancer: an advance |
| DONG Wenyan,SUN Dezheng,FANG Min,SHENG Yuan* |
(Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200433, China
*Corresponding author) |
| Abstract: |
| Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are oncogenic drivers in multiple solid tumors, and they are also important clinical biomarkers. NTRK fusion-positive thyroid cancer (TC) exhibits distinctive clinicopathological features. Patients with advanced, metastatic, or iodine-refractory TC should receive evaluation of NTRK fusion status. However, there have been no authoritative recommendations or standardized procedures for the diagnosis and treatment of NTRK fusions in TC. This review discusses the research advances regarding NTRK fusion-positive TC, summarizes the clinicopathological features of the disease, and outlines the current statuses of NTRK fusion detection and targeted therapeutic agents. |
| Key words: thyroid neoplasms neurotrophic receptor tyrosine kinase gene fusion targeted therapy |
